Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-064412
Filing Date
2025-05-06
Accepted
2025-05-06 16:01:26
Documents
89
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q srpt-20250331.htm   iXBRL 10-Q 3395201
2 EX-31.1 srpt-ex31_1.htm EX-31.1 13356
3 EX-31.2 srpt-ex31_2.htm EX-31.2 13407
4 EX-32.1 srpt-ex32_1.htm EX-32.1 9525
5 EX-32.2 srpt-ex32_2.htm EX-32.2 9436
  Complete submission text file 0000950170-25-064412.txt   12603103

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT srpt-20250331.xsd EX-101.SCH 1551460
92 EXTRACTED XBRL INSTANCE DOCUMENT srpt-20250331_htm.xml XML 2460430
Mailing Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142
Business Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 617-274-4000
Sarepta Therapeutics, Inc. (Filer) CIK: 0000873303 (see all company filings)

EIN.: 930797222 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-14895 | Film No.: 25917086
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)